You say that to justify the current market cap the NPAT should be $100M at a minimum. That would be a PE ratio of 15.9.
I'm not sure that you are being serious.
Do you realise that such a P/E would be seriously out of wack for a growth stock?
For comparison, here are the P/Es of two very large Aussie health tech stocks: Cochlear's is 75 and Resmed's is 52. Neither has the same potential growth rate as PNV.
I suggest that with an NPAT of $100M the likely P/E of Polynovo would be anywhere from 75 to 275 given that it's potential for high growth would still be great. And that would give an sp range of $12 to $40.
I don't expect an NPAT of $100M to come next year or the next but it won't be long after.
Ann: FY21 BTM Revenue Results, page-128
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.04 |
Change
-0.030(1.45%) |
Mkt cap ! $1.409B | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.11 | $2.03 | $1.727M | 838.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 299194 | $2.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.04 | 1559 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |